Table 3.
Crude and age standardized incidence rates per 100,000 (95% confidence interval): HMRN Sept 2004 to Aug 2013.
| Crude | European 2013 | European 1976 | USA 2001 | World 1996 | |
|---|---|---|---|---|---|
| All myeloid malignancies | 16.28 (15.84–16.72) | 19.06 (18.89–19.23) | 12.41 (12.29–12.52) | 13.64 (13.51–13.76) | 8.76 (8.58–8.67) |
| Acute myeloid leukaemia | 4.39 (4.16–4.63) | 5.06 (4.97–5.15) | 3.48 (3.41–3.54) | 3.75 (3.69–3.82) | 2.58 (2.52–2.63) |
| AML-not otherwise specified | 2.68 (2.50–2.86) | 3.13 (3.06–3.20) | 2.00 (1.95–2.05) | 2.24 (2.19–2.29) | 1.41 (1.37–1.46) |
| AML with myelodysplasia-related changes | 0.61 (0.53–0.70) | 0.73 (0.69–0.76) | 0.49 (0.46–0.52) | 0.50 (0.48–0.53) | 0.35 (0.32–0.37) |
| AML with NPM mutation | 0.32 (0.26–0.39) | 0.37 (0.34–0.40) | 0.25 (0.23–0.28) | 0.28 (0.25–0.30) | 0.18 (0.16–0.20) |
| Acute promyelocytic leukaemia | 0.28 (0.23–0.35) | 0.30 (0.27–0.33) | 0.27 (0.25–0.30) | 0.27 (0.25–0.30) | 0.24 (0.21–0.27) |
| AML, core binding factor | 0.20 (0.15–0.25) | 0.20 (0.18–0.23) | 0.20 (0.17–0.22) | 0.20 (0.17–0.22) | 0.18 (0.16–0.21) |
| AML, probable therapy related | 0.19 (0.15–0.24) | 0.22 (0.20–0.25) | 0.15 (0.13–0.17) | 0.16 (0.14–0.18) | 0.11 (0.09–0.12) |
| AML with MLL(11q23) | 0.08 (0.05–0.11) | 0.07 (0.05–0.09) | 0.09 (0.06–0.11) | 0.08 (0.06–0.10) | 0.10 (0.07–0.12) |
| Myelodysplastic syndromes (MDS) | 3.72 (3.51–3.93) | 4.44 (4.35–4.52) | 2.58 (2.53–2.64) | 3.01 (2.95–3.07) | 1.67 (1.63–1.71) |
| Refractory cytopenia with multilineage dysplasia | 1.55 (1.41–1.69) | 1.85 (1.80–1.91) | 1.07 (1.03–1.10) | 1.25 (1.21–1.29) | 0.68 (0.65–0.70) |
| Refractory anaemia with excess blasts | 1.43 (1.30–1.56) | 1.69 (1.64–1.74) | 1.02 (0.98–1.06) | 1.16 (1.12–1.20) | 0.68 (0.65–0.71) |
| Refractory anaemia with ring sideroblasts | 0.66 (0.58–0.76) | 0.79 (0.76–0.83) | 0.43 (0.41–0.46) | 0.53 (0.50–0.56) | 0.27 (0.25–0.28) |
| MDS (5q-) | 0.08 (0.05–0.12) | 0.10 (0.07–0.12) | 0.06 (0.05–0.08) | 0.07 (0.05–0.08) | 0.04 (0.03–0.05) |
| Myeloproliferative neoplasms (MPN) | 7.25 (6.96–7.55) | 8.47 (8.35–8.58) | 5.73 (5.64–5.81) | 6.13 (6.05–6.22) | 4.02 (3.96–4.09) |
| Chronic MPNs | 5.66 (5.40–5.93) | 6.65 (6.55–6.76) | 4.37 (4.30–4.44) | 4.74 (4.66–4.81) | 3.02 (2.97–3.07) |
| Chronic myeloid leukaemia | 0.99 (0.88–1.10) | 1.10 (1.06–1.14) | 0.89 (0.86–0.93) | 0.90 (0.86–0.93) | 0.69 (0.66–0.72) |
| Myelofibrosis | 0.51 (0.44–0.60) | 0.61 (0.58–0.65) | 0.38 (0.35–0.40) | 0.42 (0.39–0.44) | 0.25 (0.23–0.27) |
| Systemic mastocytosis | 0.08 (0.05–0.12) | 0.09 (0.06–0.12) | 0.08 (0.05–0.10) | 0.07 (0.05–0.09) | 0.06 (0.04–0.08) |
| MDS/MPN | 0.92 (0.82–1.03) | 1.10 (1.06–1.15) | 0.62 (0.59–0.65) | 0.74 (0.71–0.78) | 0.40 (0.38–0.43) |
| Chronic myelomonocytic leukaemia | 0.74 (0.65–0.84) | 0.89 (0.85–0.93) | 0.49 (0.46–0.52) | 0.60 (0.57–0.63) | 0.30(0.28–0.32) |
| MDS/MPN, unclassified | 0.09 (0.06–0.13) | 0.11 (0.09–0.14) | 0.06 (0.05–0.08) | 0.07 (0.06–0.09) | 0.04 (0.03–0.05) |
| Atypical chronic myeloid leukaemia | 0.07 (0.05–0.11) | 0.09 (0.07–0.11) | 0.05 (0.04–0.07) | 0.06 (0.04–0.07) | 0.04 (0.03–0.05) |
| Males | |||||
| All myeloid malignancies | 18.42 (17.75–19.11) | 25.14 (24.82–25.45) | 15.63 (15.44–15.83) | 17.7 (17.7–17.92) | 10.76 (10.48–10.62) |
| Acute myeloid leukaemia | 4.94 (4.60–5.30) | 6.50 (6.34–6.66) | 4.29 (4.19–4.40) | 4.74 (4.62–4.86) | 3.11 (3.02–3.20) |
| AML-not otherwise specified | 3.05 (2.78–3.34) | 4.17 (4.04–4.30) | 2.60 (2.51–2.69) | 2.95 (2.86–3.05) | 1.80 (1.73–1.88) |
| AML with myelodysplasia-related changes | 0.78 (0.64–0.93) | 1.02 (0.95–1.10) | 0.67 (0.61–0.72) | 0.70 (0.64–0.76) | 0.46 (0.42–0.50) |
| AML with NPM mutation | 0.27 (0.19–0.36) | 0.35 (0.28–0.42) | 0.23 (0.18–0.28) | 0.27 (0.21–0.32) | 0.16 (0.12–0.20) |
| Acute promyelocytic leukaemia | 0.30 (0.22–0.40) | 0.32 (0.26–0.38) | 0.29 (0.24–0.34) | 0.29 (0.24–0.34) | 0.25 (0.20–0.30) |
| AML, core binding factor | 0.26 (0.19–0.36) | 0.28 (0.22–0.34) | 0.26 (0.21–0.31) | 0.26 (0.21–0.32) | 0.24 (0.18–0.29) |
| AML, probable therapy related | 0.18 (0.12–0.26) | 0.25 (0.19–0.30) | 0.15 (0.11–0.19) | 0.26 (0.21–0.32) | 0.10 (0.7–0.14) |
| AML with MLL(11q23) | 0.06 (0.03–0.12) | 0.06 (0.03–0.09) | 0.07 (0.03–0.11) | 0.17 (0.13–0.21) | 0.08 (0.03–0.12) |
| Myelodysplastic syndromes (MDS) | 5.10 (4.75–5.47) | 7.41 (7.24–7.59) | 4.10 (4.00–4.20) | 4.98 (4.86–5.10) | 2.55 (2.48–2.62) |
| Refractory cytopenia with multilineage dysplasia | 2.34 (2.10–2.59) | 3.41 (3.29–3.53) | 1.87 (1.80–1.94) | 2.28 (2.20–2.36) | 1.15 (1.11–1.20) |
| Refractory anaemia with excess blasts | 1.87 (1.66–2.10) | 2.68 (2.57–2.79) | 1.52 (1.46–1.59) | 1.82 (1.74–1.89) | 0.97 (0.92–1.01) |
| Refractory anaemia with ring sideroblasts | 0.87 (0.73–1.03) | 1.28 (1.21–1.36) | 0.69 (0.64–0.73) | 0.86 (0.80–0.91) | 0.42 (0.39–0.45) |
| MDS (5q-) | 0.03 (0.01–0.07) | 0.04 (0.01–0.07) | 0.02 (0.00–0.04) | 0.03 (0.00–0.05) | 0.01 (0.00–0.02) |
| Myeloproliferative neoplasms (MPN) | 7.18 (6.77–7.61) | 9.45 (9.26–9.64) | 6.28 (6.16–6.41) | 6.79 (6.65–6.92) | 4.37 (4.28–4.46) |
| Chronic MPNs | 5.27 (4.91–5.64) | 7.08 (6.91–7.25) | 4.55 (4.45–4.66) | 4.99 (4.87–5.11) | 3.10 (3.02–3.19) |
| Chronic myeloid leukaemia | 1.21 (1.05–1.40) | 1.41 (1.33–1.49) | 1.14 (1.07–1.20) | 1.15 (1.08–1.21) | 0.87 (0.82–0.93) |
| Myelofibrosis | 0.64 (0.52–0.77) | 0.88 (0.81–0.95) | 0.54 (0.49–0.58) | 0.59 (0.54–0.64) | 0.35 (0.32–0.38) |
| Systemic mastocytosis | 0.05 (0.02–0.10) | 0.06 (0.03–0.10) | 0.04 (0.02–0.07) | 0.04 (0.02–0.07) | 0.03 (0.01–0.05) |
| MDS/MPN | 1.20 (1.04–1.39) | 1.78 (1.69–1.88) | 0.96 (0.90–1.02) | 1.19 (1.12–1.26) | 0.59 (0.54–0.64) |
| Chronic myelomonocytic leukaemia | 0.98 (0.83–1.14) | 1.45 (1.37–1.54) | 0.77 (0.72–0.83) | 0.97 (0.91–1.03) | 0.47 (0.43–0.50) |
| MDS/MPN, unclassified | 0.11 (0.06–0.17) | 0.16 (0.11–0.21) | 0.09 (0.06–0.12) | 0.11 (0.07–0.14) | 0.05 (0.03–0.07) |
| Atypical chronic myeloid leukaemia | 0.11 (0.06–0.17) | 0.16 (0.11–0.21) | 0.09 (0.06–0.12) | 0.10 (0.07–0.13) | 0.06 (0.04–0.08) |
| Females | |||||
| All myeloid malignancies | 14.26 (13.69–14.85) | 15.07 (14.87–15.28) | 10.10 (9.95–10.25) | 10.96 (10.81–11.11) | 7.33 (7.09–7.21) |
| Acute myeloid leukaemia | 3.87 (3.58–4.19) | 4.07 (3.96–4.18) | 2.86 (2.78–2.95) | 2.16 (2.08–2.23) | 3.06 (2.98–3.15) |
| AML-not otherwise specified | 2.32 (2.10–2.57) | 2.41 (2.32–2.50) | 1.55 (1.48–1.62) | 1.74 (1.67–1.81) | 1.10 (1.04–1.16) |
| AML with myelodysplasia-related changes | 0.46 (0.36–0.57) | 0.51 (0.45–0.56) | 0.36 (0.31–0.40) | 0.36 (0.31–0.40) | 0.26 (0.21–0.30) |
| AML with NPM mutation | 0.37 (0.29–0.48) | 0.40 (0.35–0.46) | 0.28 (0.23–0.32) | 0.29 (0.25–0.34) | 0.20 (0.16–0.24) |
| Acute promyelocytic leukaemia | 0.27 (0.19–0.36) | 0.28 (0.23–0.33) | 0.26 (0.22–0.31) | 0.26 (0.21–0.31) | 0.23 (0.18–0.27) |
| AML, core binding factor | 0.14 (0.09–0.21) | 0.14 (0.10–0.19) | 0.14 (0.10–0.18) | 0.14 (0.10–0.18) | 0.13 (0.09–0.18) |
| AML, probable therapy related | 0.20 (0.14–0.28) | 0.22 (0.18–0.26) | 0.16 (0.13–0.19) | 0.16 (0.12–0.19) | 0.11 (0.08–0.14) |
| AML with MLL(11q23) | 0.09 (0.05–0.15) | 0.09 (0.05–0.12) | 0.10 (0.06–0.14) | 0.10 (0.06–0.14) | 0.12 (0.07–0.16) |
| Myelodysplastic syndromes (MDS) | 2.41 (2.18–2.66) | 2.53 (2.44–2.62) | 1.54 (1.48–1.61) | 1.75 (1.68–1.82) | 1.04 (0.98–1.10) |
| Refractory cytopenia with multilineage dysplasia | 0.80 (0.67–0.95) | 0.85 (0.79–0.90) | 0.51 (0.47–0.55) | 0.58 (0.54–0.62) | 0.33 (0.30–0.37) |
| Refractory anaemia with excess blasts | 1.01 (0.86–1.17) | 1.06 (0.99–1.13) | 0.68 (0.62–0.73) | 0.75 (0.69–0.80) | 0.48 (0.42–0.53) |
| Refractory anaemia with ring sideroblasts | 0.47 (0.37–0.59) | 0.48 (0.43–0.52) | 0.26 (0.23–0.29) | 0.32 (0.29–0.35) | 0.16 (0.14–0.18) |
| MDS (5q-) | 0.13 (0.08–0.20) | 0.15 (0.11–0.19) | 0.10 (0.07–0.13) | 0.10 (0.07–0.13) | 0.07 (0.05–0.09) |
| Myeloproliferative neoplasms (MPN) | 7.31 (6.91–7.74) | 7.79 (7.64–7.94) | 5.30 (5.19–5.41) | 5.68 (5.57–5.79) | 3.75 (3.67–3.84) |
| Chronic MPNs | 6.03 (5.66–6.41) | 6.42 (6.28–6.55) | 4.27 (4.17–4.36) | 4.61 (4.51–4.71) | 2.98 (2.90–3.05) |
| Chronic myeloid leukaemia | 0.78 (0.65–0.93) | 0.83 (0.78–0.89) | 0.67 (0.62–0.72) | 0.68 (0.63–0.73) | 0.52 (0.48–0.57) |
| Myelofibrosis | 0.40 (0.31–0.51) | 0.42 (0.37–0.47) | 0.25 (0.22–0.29) | 0.29 (0.25–0.32) | 0.16 (0.14–0.19) |
| Systemic mastocytosis | 0.11 (0.06–0.17) | 0.12 (0.08–0.16) | 0.11 (0.07–0.15) | 0.10 (0.07–0.14) | 0.09 (0.06–0.12) |
| MDS/MPN | 0.66 (0.54–0.79) | 0.68 (0.62–0.73) | 0.40 (0.35–0.44) | 0.47 (0.42–0.51) | 0.27 (0.23–0.31) |
| Chronic myelomonocytic leukaemia | 0.53 (0.42–0.65) | 0.54 (0.49–0.59) | 0.29 (0.26–0.33) | 0.36 (0.32–0.40) | 0.18 (0.16–0.21) |
| MDS/MPN, unclassifiable | 0.08 (0.04–0.13) | 0.08 (0.05–0.11) | 0.05 (0.03–0.07) | 0.05 (0.03–0.08) | 0.03 (0.02–0.04) |
| Atypical chronic myeloid leukaemia | 0.04 (0.01–0.08) | 0.04 (0.01–0.07) | 0.03 (0.00–0.05) | 0.03 (0.01–0.05) | 0.02 (0.00–0.04) |